Barzolvolimab Shows Promise in CSU
Chronic spontaneous urticaria (CSU) is getting a lot of attention these days as researchers close in on the role mast cells play in causing hives. Top-line results from a phase 2 trial show that barzolvolimab (anti-KIT monoclonal antibody) improves symptoms in patients with antihistamine-refractory CSU. “Barzolvolimab successfully decreased disease activity in patients with moderate to […]